NCT01855945View on ClinicalTrials.gov

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

PHASE1CompletedINTERVENTIONAL
Enrollment

627

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Prophylaxis of A/H3N2v Influenza
Interventions
BIOLOGICAL

Swine Influenza

Comparison of different dosages of vaccines

Trial Locations (11)

14609

44, Rochester Clinical Research Inc., Rochester

27609

50, PMG Research of Raleigh, Raleight

40509

43, Central Kentucky Research Associates, Lexington

66213

46, Johnson County Clinical Trials, Lenexa

67207

49, Heartland Research Associates, LLC, Wichita

70006

41, Benchmark Research, Metairie

75234

42, Research Acros, Dallas

84109

"48, J. Lewis Research, Inc.", Salt Lake City

95822

47, Benchmark Research, Sacramento

96001

51, Northern California Clinical Research Center, Redding

02886

45, Omega Medical Research, Warwick

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY